- Inovio Pharmaceuticals (INO) acquires the global (ex-China) rights to therapies for Alzheimer's disease and multiple sclerosis based on the work of DNA researcher Dr. Ben Wang from Fudan University's Shanghai Medical College.
- The therapies work by generating inducible regulatory T cells (iTreg). The cells are involved in shutting down immune responses after they have successfully eliminated invading organisms. They have potential in preventing autoimmune and inflammatory diseases.
- No financial terms are disclosed.
From other sites
Video at CNBC.com (Apr 8, 2015)
at CNBC.com (Nov 24, 2014)
Video at CNBC.com (Nov 24, 2014)
at CNBC.com (Oct 21, 2014)
at CNBC.com (Oct 2, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs